Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Announces Retirement of Executive VP Barry Flannelly
- Early notable gainers among liquid option names on January 7th
- Incyte price target raised to $75 from $74 at RBC Capital
- Early notable gainers among liquid option names on December 31st
- Incyte price target raised to $70 from $68 at Wells Fargo